Where a plaintiff has brought a securities class action over a clinical trial for a hearing loss treatment, the defendants’ motion to dismiss should be allowed because the plaintiff has failed to plead facts with particularity establishing (1) false or misleading statements and (2) a strong inference of scienter. “Lead plaintiff Julian Quinones (‘Quinones’) brings
Frequency Therapeutics announced it will scrap development of a drug called FX-322 after testing failed to show improvement in speech perception in people with noise-induced sensorineural hearing loss.
Scientists at Frequency Therapeutics were the first to demonstrate that therapeutic concentrations of FX-322 in the human cochlea are associated with statistically significant improvements in hearing function. These clinical trials administered the therapeutic to one ear, while the other ear in the same participant was used as a control and measured the percentage of participants that exceeded an absolute 10% improvement in speech perception.
Research out of Woburn-based biotech company Frequency Therapeutics might allow people to regenerate their sense of hearing. Although there’s still years of work to go, researchers say preliminary data released Sunday show the drug’s early promise.